Advertisement
Research Updates

Treatment

  • Extending Remissions in Lung Cancer

    Immune checkpoint inhibitors are effective against non-small cell lung cancer in some patients. Researchers are investigating who benefits from the drugs and when they should be administered for maximum impact.

    by Natalie Slivinski

  • TILs in Solid Tumors

    With the FDA’s approval of the first tumor‑infiltrating lymphocyte (TIL) therapy to treat advanced melanoma, researchers seek to expand this type of cellular therapy to other solid tumors.

    by Kendall K. Morgan

  • Forward Look

    The Time Factor

    Oncologist and researcher Arjun Gupta discusses time toxicity and why it is important.

    by Ashley P. Taylor

  • Forward Look

    Imaging Predicts Early Response to Melanoma Immunotherapy

    Research shows a scan can reveal treatment responses just one week after people with melanoma start immunotherapy.

    by Anna Azvolinsky

  • Forward Look

    A Different Chemotherapy Approach for Ovarian Cancer

    Study suggests heated chemotherapy delivered to the abdominal cavity extends survival in advanced ovarian cancer.

    by Kris Conner

  • Forward Look

    Some Breast Cancer Patients Can Skip Radiation

    Research suggests postmenopausal women over 50 with low-risk hormone receptor-positive breast cancer may forgo radiation after surgery.

    by Darcy Lewis

  • Progress Against Cancer

    New research fuels progress in cancer survival, prevention and side effect management.

  • Vaccines Spark Activity in Pancreatic Cancer

    Scientists thought pancreatic cancer wouldn’t respond to immunotherapy. Now research has found vaccines can trigger the immune system to fight the disease.

    by Thomas Celona

  • Improving Glioblastoma Treatment

    Phase I clinical trial finds adding a radiosensitizer may improve radiation’s ability to kill this fast-growing brain cancer.

    by Thomas Celona

  • Results That Matter

    Cancer medications granted accelerated approval are often confirmed despite not demonstrating a benefit in overall survival or quality of life.

    by Eric Fitzsimmons